Evidence map›Paper›PMID 41382971›Full record

ArticlemAbs2026

Beyond sequence similarity: ML-powered identification of pHLA off-targets for TCR-mimic antibodies using high throughput binding kinetics.

Alexander Sinclair, Stefan Krämer, Christoph Reinhart, Jennifer Stehle, Simon Schuster, Tobias Herz, Hoor Al Hasani, Pranav Hamde, Oliver Selinger, Joerg Birkenfeld

Abstract read
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alexander SinclairR&D Department, BioCopy GmbH, Emmendingen, Germany.
Stefan KrämerR&D Department, BioCopy GmbH, Emmendingen, Germany.ORCID 0000-0002-0071-9344
Christoph ReinhartR&D Department, BioCopy AG, Basel, Switzerland.ORCID 0000-0002-3580-1807
Jennifer StehleR&D Department, BioCopy GmbH, Emmendingen, Germany.
Simon SchusterR&D Department, BioCopy GmbH, Emmendingen, Germany.ORCID 0009-0001-2533-8847
Tobias HerzR&D Department, BioCopy GmbH, Emmendingen, Germany.ORCID 0000-0001-9461-1993
Hoor Al HasaniR&D Department, BioCopy GmbH, Emmendingen, Germany.ORCID 0000-0002-0431-845X
Pranav HamdeR&D Department, BioCopy GmbH, Emmendingen, Germany.
Oliver SelingerR&D Department, BioCopy GmbH, Emmendingen, Germany.ORCID 0000-0001-9723-2809
Joerg BirkenfeldR&D Department, BioCopy AG, Basel, Switzerland.ORCID 0000-0002-0611-0396

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell receptor mimic (TCRm) antibodies are an emerging class of tumor-targeting agents used in advanced immunotherapies such as bispecific T-cell engagers and CAR-T cells. Unlike conventional antibodies, TCRms are designed to recognize peptide - human leukocyte antigen (pHLA) complexes that present intracellular tumor-derived peptides on the cell surface. Due to the typically low surface abundance and high sequence similarity of pHLAs, TCRms require high affinity and exceptional specificity to avoid off-target toxicity. Conventional methods for off-target identification such as sequence similarity searches, motif-based screening, and structural modeling focus on the peptide and are limited in detecting cross-reactive peptides with little or no sequence homology to the target. To address this gap, we developed EpiPredict, a TCRm-specific machine learning framework trained on high-throughput kinetic off-target screening data. EpiPredict learns an antibody-specific mapping from peptide sequence to binding strength, enabling prediction of interactions with unmeasured pHLA sequences, including sequence-dissimilar peptides. We applied EpiPredict to two distinct TCRms targeting the cancer-testis antigen MAGE-A4. The model successfully predicted multiple off-targets with minimal sequence similarity to the intended epitope, many of which were experimentally validated via T2 cell binding assays. These findings establish EpiPredict as a valuable tool for lead optimization of TCRms, enabling the identification of antibody-specific off-targets beyond the scope of traditional peptide-centric methods and supporting the preclinical de-risking of TCRm-based therapies.

Indexed as

Antigens, NeoplasmHLA AntigensPeptidesReceptors, Antigen, T-CellHigh-Throughput Screening AssaysHumansKineticsMachine LearningAntigens, NeoplasmHLA AntigensPeptidesReceptors, Antigen, T-CellBinding kineticsBLIHLAmachine learningMAGE-A4MHCoff-target toxicitypeptide-MHC complexpHLApMHCpreclinical de-riskingSCORET2-bindingTCR-like antibodyX-scan

Identifiers

PMID41382971
PMCPMC12710896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.